BioTuesdays

Category - Markets

Apollo Endosurgery
Markets

Stifel starts Apollo Endosurgery at buy; PT $12

Stifel launched coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and $12 price target. The stock closed at $8.59 on Dec. 8. Apollo Endosurgery is a medical technology company focused on design...

December 9, 2021
Bolt-Biotherapeutics
Markets

Stifel cuts Bolt Biotherapeutics PT to $19 from $34

Stifel reduced its price target for Bolt Biotherapeutics (NASDAQ:BOLT) to $19 from $34, but maintained its “buy” rating, after the company presented interim clinical data from an ongoing Phase 1/2 study of BDC-1001, its...

December 6, 2021
NeuroOne
Markets

AGP starts NeuroOne Medical at buy; PT $5.75

Alliance Global Partners launched coverage of NeuroOne Medical Technologies (NASDAQ:NMTC) with a “buy” rating and price target of $5.75. The stock closed at $2.09 on Dec. 2. NeuroOne’s flexible, thin-film...

December 3, 2021
AcelRx Pharma Logo
Markets

Cantor cuts AcelRx PT to $4 from $9; maintains OW

Cantor Fitzgerald reduced its price target for AcelRx Pharmaceuticals (NASDAQ:ACX) to $4 from $9, but maintained its “overweight” rating, citing a revised ramp in Dsuvia sales, as well as recent acquisitions and an...

December 2, 2021
Point Biopharma Logo
Markets

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

December 1, 2021
Citius Logo
Markets

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

November 30, 2021
Freeline Therapeutics
Markets

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

November 29, 2021
Acurx Pharmaceuticals
Markets

Maxim starts Acurx Pharma at buy; PT $12

Maxim Group initiated coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $12 price target. The stock closed at $4.89 on Nov. 26. Acurx is developing ibezapolstat, a member of an emerging new class...

November 29, 2021
Mdx Health
Markets

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

November 29, 2021